NCT02855346View on ClinicalTrials.gov

PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

August 18, 2017

Study Completion Date

August 18, 2017

Conditions
HIV Prevention
Interventions
COMBINATION_PRODUCT

200 mg of DPV + 320 mg LNG

DPV VR, containing 200 mg DPV

COMBINATION_PRODUCT

200 mg of DPV

DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG

Trial Locations (2)

15213

Magee Women's Hospital of UPMC, Pittsburgh

35294

University of Alabama Hospital, Birmingham

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

International Partnership for Microbicides, Inc.

INDUSTRY

NCT02855346 - PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel | Biotech Hunter | Biotech Hunter